Li et al. give a comprehensive review of the severe problem of macrolide resistance to common pathogens in China. Various common pathogens have shown high resistance rates and high resistance level to macrolides in Chinese children. Yu et al. give a review of penicillin binding protein and S. pyogenes (group A Streptococcus, GAS) with reduced β-lactam susceptibility. They summarize the current published data on GAS penicillin binding proteins and β-lactam susceptibility, to explore the relationship between them, and to be alert to the emergence of GAS with reduced susceptibility to β-lactams. Cao et al. present a case of spinal muscular atrophy with extensively drug-resistant Acinetobacter baumannii pneumonia treated with nebulization combined with intravenous polymyxin B. They present their experience in the diagnosis and treatment of this case and review it in the context of the literature. Wang et al. provide an experimental study about a novel mechanisms of macrolide resistance revealed by in vitro selection and genome analysis in Mycoplasma pneumoniae. This study presented the first in vitro data of induced midecamycin resistance in M. pneumoniae and the potential advantage of using midecamycin as an alternative first treatment choice for M. pneumoniae infections in patients. Zhuang et al. review the trends and challenges of multi-drug resistance in childhood tuberculosis. This review provides an overview of the current epidemiology of childhood tuberculosis (TB) and drug-resistant tuberculosis (DR-TB), including prevalence, incidence, and mortality. They highlight the urgent need for improved diagnosis and treatment of DR-TB in children.

Guo et al. provide a dynamic change of serotype distribution and antimicrobial resistance of pneumococcal isolates since PCV13 administration and COVID-19 control in Urumqi, China. Su et al. describe the 10-year trends in multicenter investigation in China about the antibiotic susceptibility and clonal distribution of Staphylococcus aureus from pediatric skin and soft tissue infections. Wu et al. present an antimicrobial resistance profile of methicillin-resistant S. aureus isolates in children reported from the Infectious Disease Surveillance of Pediatrics (ISPED) surveillance of bacterial resistance, 2016–2021. Wang et al. present the characterization of resistance genes and plasmids from sick children caused by Salmonella enterica resistance to azithromycin in Shenzhen, China. Kawata et al. describe the fecal carriage rate of extended-spectrum β-lactamase–producing or carbapenem-resistant Enterobacterales among Japanese infants in the community at the 4-month health examination in a rural city. Xiao et al. present the antibiotic susceptibility of Escherichia coli isolated from neonates admitted to neonatal intensive care units across China from 2015 to 2020. Jiang et al. discuss the clinical significance of macrolide resistance in pediatric Mycoplasma pneumoniae infection during COVID-19 pandemic. Weidmann et al. report the assessing respiratory viral exclusion and affinity interactions through coinfection incidence in a pediatric population during the 2022 resurgence of influenza and RSV.

Peng et al. demonstrate that the vancomycin dosages of 40-60 mg/kg/d are effective and have no vancomycin-related nephrotoxicity adverse effects in children with Gram positive bacterial sepsis. Vancomycin trough concentrations >15 mg/L are not an essential target for these Gram-positive bacterial sepsis patients.

Antibiotics are a double-edged sword, and when used, we must avoid not only overuse, but also underuse. In recent years, countries around the world have introduced antibiotic action plans to control antibiotic resistance in bacteria and strictly control the clinical use of antibiotics, which has led to the underuse of clinical antibiotics (Hsia et al., 2019; Zhang et al., 2019; WHO, 2023). Yu et al. give a case report about rational use of antibiotics, in which 3 cases of septic arthritis in children caused by S. pyogenes were reported. Once S. pyogenes infection is confirmed, β-lactam antibiotics provide effective treatment, avoiding use of broad-spectrum antibiotics.

Underuse is common, as shown by: 1. not using it in time when it should be used; 2. insufficient dosage; 3. insufficient duration. These lead to an increase in bacterial infections and even epidemics. This phenomenon can be confirmed by the outbreak of GAS epidemic in the UK in 2022 (The Lancet Microbe, 2023; Venkatesan, 2023). Based on the great controversy in the implementation of β-lactam antibiotic skin tests, especially the controversial cephalosporin skin tests in pediatrics, the mechanism and reasons of anaphylaxis to β-lactam antibiotics, the significance of β-lactam antibiotic skin tests, the current state of β-lactam antibiotic skin tests at home and abroad, and the problems of domestic and international skin tests were analyzed to determine a unified standard of β-lactam antibiotic skin tests in pediatrics to prevent and decrease adverse drug reactions, avoid waste of drugs, and a large amount of manpower and material resource consumption. Gao et al. review the state and consideration for skin test of β-lactam antibiotics in pediatrics.

Multi-drug resistant TB (MDR-TB) is often undiagnosed in children due to lack of awareness or under-diagnosis, and the target for children’s DR-TB treatment has only been met in 15% of goals. However, due to age and weight differences, adults and children require different dosages. New medications such as bedaquiline and delamanid have been approved for treating DR-TB. Zhu et al. give a comprehensive review of the advances of new drugs bedaquiline and delamanid in the treatment of multi-drug resistant tuberculosis in children. Their review highlights the use of bedaquiline and delamanid as potential treatments for children with MDR-TB. They summarize their development history, efficacy, safety and potential adverse effects. Further research is necessary to determine the optimal use of these drugs for treating MDR-TB in children.

The problem of antimicrobial resistance in children cannot be ignored. We sincerely thank all contributors and reviewers for their support in putting this timely Research Topic together and hope that the readers will find useful answers to their questions.

DY: Writing – original draft, Writing – review & editing. YZ: Funding acquisition, Writing – review & editing. AS: Writing – review & editing. FW: Writing – review & editing. AD: Writing – review & editing. MK: Writing – review & editing. YY: Funding acquisition, Resources, Writing – review & editing.